HARMONY Partner and Research Project Leader Thomas Weber, Universitätsklinikum Halle (Saale) der Martin-Luther-Universität Halle-Wittenberg, is presenting at the 8th Workshop ELI “T-cell lymphoma in Europe” . The workshop takes place on 29 and 30 September 2022 in Amsterdam, The Netherlands
ELI is the European Lymphoma Institute, regrouping top European specialists in the field of lymphoma within a net dedicated to research, training and education. To date, thirteen European academic research groups have come together in an effort to define strategies to analyse and characterize this cancer, common diagnostic procedures and therapeutic standards as well as to facilitate clinical and fundamental research at the European level.
View the program of the 8th ELI Workhsop here >
Dr. Thomas Weber will introduce the HARMONY Alliance and elaborate on the NHL research project. The second part of his presentation is about German national T-Cell Lymphoma Registry and Biobank German Lymphoma Alliance (GLA) Ostdeutsche Studiengruppe für Hämatologie und Onkologie (OSHO).
The HARMONY Non-Hodgkin Lymphoma (NHL) Research Project currently running is titles: Using big data to optimize outcomes in T-cell Non-Hodgkin Lymphomas. The aim of this project is to better understand the molecular basis of T-cell lymphomas, leading to improved diagnosis and prognosis prediction, better disease sub classification and improved knowledge to guide treatment decisions. The molecular pathogenesis of T-cell non-Hodgkin lymphomas (NHLs) is complex and only partially understood. Due to the rarity of these diseases, attempts to better elucidate the impact of genomics on prognostication and treatment have been hampered by a paucity of data. Large patient cohorts - accessed via the HARMONY Data Platform - are therefore needed to bridge this gap and improve molecular understanding and, in turn, treatment outcomes in T-cell lymphomas.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
